enteral application News
-
NEW: Interactive Winch Configurator Tool
InterOcean Systems launches a new online Winch Configurator tool. Allows users to enter their cable handling application requirements to generate a complete spooling chart, along with a cost estimator and horsepower estimator. New Winch Configurator tool can be found here: InterOcean Systems Winch Configurator ...
-
MV BioTherapeutics to present at 5th Microbiome Movement - Drug Development Europe
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota ...
-
Succesfull Bio Digital 2020
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global ...
-
Environment: 17 companies nominated for the 2014 European Business Awards for the Environment
The shortlist for the 2014 European Business Awards for the Environment (EBAE) has been revealed, following a two-day jury meeting in Rome, Italy. The 17 finalists come from 10 countries. The winners will be announced at a ceremony in Lyon on 1st December 2014 at the Pollutec exhibition of environmental technologies in Lyon, France. The European Business Awards for the Environment are awarded to ...
-
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Immune-Onc ...
-
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the initiation of AcQForce PFA-CE, a new clinical study that will evaluate the safety and performance of the company’s focal force sensing Pulsed Field Ablation (PFA) catheter and system in combination with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you